PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Jazz Pharmaceuticals plc (JAZZ)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

IE00B4Q5ZN47

CUSIP

00B4Q5ZN4

Sector

Healthcare

IPO Date

Jun 1, 2007

Highlights

Market Cap

$7.41B

EPS (TTM)

$7.06

PE Ratio

17.35

PEG Ratio

0.84

Total Revenue (TTM)

$3.99B

Gross Profit (TTM)

$3.11B

EBITDA (TTM)

$1.42B

Year Range

$99.06 - $134.17

Target Price

$181.05

Short %

9.38%

Short Ratio

6.16

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
JAZZ vs. BMRN JAZZ vs. SMG JAZZ vs. SPY JAZZ vs. HD JAZZ vs. VOO JAZZ vs. CRSP JAZZ vs. MKL
Popular comparisons:
JAZZ vs. BMRN JAZZ vs. SMG JAZZ vs. SPY JAZZ vs. HD JAZZ vs. VOO JAZZ vs. CRSP JAZZ vs. MKL

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Jazz Pharmaceuticals plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


200.00%300.00%400.00%500.00%600.00%JulyAugustSeptemberOctoberNovemberDecember
586.63%
282.22%
JAZZ (Jazz Pharmaceuticals plc)
Benchmark (^GSPC)

Returns By Period

Jazz Pharmaceuticals plc had a return of -1.02% year-to-date (YTD) and -0.34% in the last 12 months. Over the past 10 years, Jazz Pharmaceuticals plc had an annualized return of -3.23%, while the S&P 500 had an annualized return of 11.01%, indicating that Jazz Pharmaceuticals plc did not perform as well as the benchmark.


JAZZ

YTD

-1.02%

1M

3.53%

6M

8.04%

1Y

-0.34%

5Y*

-4.51%

10Y*

-3.23%

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of JAZZ, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-0.23%-3.11%1.28%-8.03%-4.97%1.41%3.30%5.20%-3.94%-1.24%10.51%-1.02%
2023-1.66%-10.38%4.22%-4.00%-8.76%-3.27%5.20%9.92%-9.71%-1.87%-6.92%4.03%-22.79%
20229.03%-1.07%13.28%2.92%-6.58%4.23%0.03%-0.54%-14.13%7.88%9.12%1.53%25.05%
2021-5.79%8.06%-2.18%0.02%8.35%-0.28%-4.57%-22.30%-1.14%2.17%-9.90%6.28%-22.81%
2020-3.97%-20.07%-12.95%10.54%8.23%-7.53%-1.89%24.15%6.10%1.06%-2.35%17.30%10.56%
20191.56%11.23%2.09%-9.22%-3.25%13.55%-2.23%-8.06%-0.01%-1.96%20.29%-1.22%20.43%
20188.24%-0.64%4.27%0.70%11.15%1.95%0.45%-1.25%-1.63%-5.54%-4.80%-18.02%-7.94%
201711.82%8.78%9.43%9.75%-8.61%6.83%-1.22%-2.77%-2.08%-3.23%-1.26%-3.64%23.50%
2016-8.41%-5.56%7.38%15.43%0.57%-6.76%6.84%-17.98%-1.90%-9.89%-5.33%5.21%-22.43%
20153.43%0.44%1.59%3.42%0.36%-1.83%9.18%-12.18%-21.33%3.37%6.78%-4.11%-14.15%
201419.83%0.19%-8.73%-2.73%5.16%3.63%-4.95%16.60%-1.45%5.16%4.89%-7.54%29.37%
20135.90%3.17%-3.90%4.36%16.49%1.12%9.93%16.06%4.88%-1.34%28.85%8.24%137.67%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of JAZZ is 44, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of JAZZ is 4444
Overall Rank
The Sharpe Ratio Rank of JAZZ is 4747
Sharpe Ratio Rank
The Sortino Ratio Rank of JAZZ is 4040
Sortino Ratio Rank
The Omega Ratio Rank of JAZZ is 3939
Omega Ratio Rank
The Calmar Ratio Rank of JAZZ is 4747
Calmar Ratio Rank
The Martin Ratio Rank of JAZZ is 4747
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for JAZZ, currently valued at 0.02, compared to the broader market-4.00-2.000.002.000.021.90
The chart of Sortino ratio for JAZZ, currently valued at 0.23, compared to the broader market-4.00-2.000.002.004.000.232.54
The chart of Omega ratio for JAZZ, currently valued at 1.03, compared to the broader market0.501.001.502.001.031.35
The chart of Calmar ratio for JAZZ, currently valued at 0.01, compared to the broader market0.002.004.006.000.012.81
The chart of Martin ratio for JAZZ, currently valued at 0.03, compared to the broader market0.0010.0020.000.0312.39
JAZZ
^GSPC

The current Jazz Pharmaceuticals plc Sharpe ratio is 0.02. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Jazz Pharmaceuticals plc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
0.02
1.90
JAZZ (Jazz Pharmaceuticals plc)
Benchmark (^GSPC)

Dividends

Dividend History


Jazz Pharmaceuticals plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-36.93%
-3.58%
JAZZ (Jazz Pharmaceuticals plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Jazz Pharmaceuticals plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Jazz Pharmaceuticals plc was 96.90%, occurring on Apr 23, 2009. Recovery took 407 trading sessions.

The current Jazz Pharmaceuticals plc drawdown is 36.93%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.9%Jun 4, 2007477Apr 23, 2009407Dec 3, 2010884
-54.54%Jul 29, 20151171Mar 23, 2020
-28.77%Feb 26, 201429Apr 7, 2014163Nov 26, 2014192
-25.64%Sep 21, 201136Nov 9, 201140Jan 9, 201276
-23.17%Apr 18, 201126May 24, 201127Jul 1, 201153

Volatility

Volatility Chart

The current Jazz Pharmaceuticals plc volatility is 7.49%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%JulyAugustSeptemberOctoberNovemberDecember
7.49%
3.64%
JAZZ (Jazz Pharmaceuticals plc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Jazz Pharmaceuticals plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Jazz Pharmaceuticals plc compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.017.3
The chart displays the price to earnings (P/E) ratio for JAZZ in comparison to other companies of the Biotechnology industry. Currently, JAZZ has a PE value of 17.3. This PE ratio falls in the average range for the industry.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.00.8
The chart displays the price to earnings to growth (PEG) ratio for JAZZ in comparison to other companies of the Biotechnology industry. Currently, JAZZ has a PEG value of 0.8. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Jazz Pharmaceuticals plc.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab